Trial Profile

The Safety and Efficacy Study of Afatinib (CT) Compared With Afatinib (GIOTRIF) in Patients With Solid Tumors (Including Mutations Identified EGFR)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 19 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Glioma; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

09 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov.
09 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
04 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com